The Iliac/SFA/Popliteal Center

Filter Your Results

 

News

 

DURABILITY II Trial

Krishna Rocha-Singh, MD, FACC, FSCAI, FSVM

March 2010—A new standard in femoropopliteal artery nitinol stent trial design.

The COBRA Trial

Sivavasavi Dinakaran, MD; Praveen Mehta, MD; Daniel Tran, MSC; Emmanouil S. Brilakis, MD; Subhash Banerjee, MD; and Tony S. Das, MD

March 2010—How will cryotherapy compare to conventional balloon angioplasty in peripheral vascular interventions?

The STROLL Study

Andrew J. Feiring, MD, FACC, FSCAI

March 2010—Nitinol self-expandable stent placement for the treatment of obstructive SFA disease.

The VIBRANT Trial

Gary M. Ansel, MD, FACC; Patrick J. Geraghty, MD, FACS; Mark Mewissen, MD; and Michael R. Jaff, DO

March 2010—Comparing bare-nitinol stents to stent grafts in long superficial femoral artery lesions in this unique trial.

The VIPER Trial

Richard R. Saxon, MD, FSIR

March 2010—With heparin bonded to the surface and a contoured edge, how will stent grafts perform in SFA revascularization?

The FlexStent Femoropopliteal Self-Expanding Stent

William A. Gray, MD

March 2010—Shortly after the release of preliminary data in New Zealand and Germany, evaluation of the FlexStent system in the United States will begin later this year.

The COMPLIANCE 360º Trial

Raymond Dattilo, MD, FACC

March 2010—The principal investigator of the COMPLIANCE 360º trial discusses its rationale, study design, and potential therapeutic implications.

The LifeStent Studies

Thomas Zeller, MD

March 2010—An overview of the trials studying bare-metal stents in the superficial femoral and popliteal artery.

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.